CLMHT-01 is under clinical development by Closed Loop Medicine and currently in Phase I for Hypertension. According to GlobalData, Phase I drugs for Hypertension have a 78% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how CLMHT-01’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CLMHT-01 overview
CLMHT-01 is under development for the treatment of hypertension. It is a single label combination product in development, linking Closed Loop Medicine’s proprietary software as a medical device (SaMD) with amlodipine.
Closed Loop Medicine overview
Closed Loop Medicine is a biotechnology company that develops combination prescription drug and software products. The company’s pipeline products include CLM-IN01 which treats insomnia; CLM-HT01 for hypertension; CLM-OB1 treats obesity; CLM-P01 which treats chronic pain. Closed Loop Medicine’s platform connects patients, clinicians and carers to provide components that can be customized to develop combined medication and digital therapy products. The company works along with various Queen Mary, Curebase, uMed, Teva, Orient Europharma, and Innovate UK, among others. Closed Loop Medicine is headquartered in Cambridge, Cambridgeshire, the UK.
For a complete picture of CLMHT-01’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
